Small HER2 Positive Breast Cancer: When is Enough?

Randeep Singh; Sudeep Gupta

doi:10.4103/ijmpo.ijmpo_12_17

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2018; 39(01): 1-3
DOI: 10.4103/ijmpo.ijmpo_12_17

Editorial Commentary

Small HER2 Positive Breast Cancer: When is Enough?

Authors

Randeep Singh

Department of Medical Oncology, Artemis Cancer Centre, Gurugram, Maharashtra
Sudeep Gupta

Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra

Abstract

Volltext

Referenzen

References
1 Joerger M, Thürlimann B, Huober J. Small HER2-positive, node-negative breast cancer: Who should receive systemic adjuvant treatment?. Ann Oncol 2011; 22: 17-23
2 Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM. et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008; 26: 5697-704
3 Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N. et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009; 27: 5693-9
4 Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R. et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008; 19: 1090-6
5 Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R. et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-20
6 Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CEJr. et al Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 2014; 32: 3744-52
7 Slamon D, Eiermann W, Robert N. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophophamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in women with Her2neu positive early breast cancer patients: BCIRG 006 study. Cancer Res 2009; 69(24 Suppl): Abstract62
8 Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H. et al Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009; 27: 6129-34
9 Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK. et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015; 372: 134-41
10 Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore IJr. et al Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: A single-group, open-label, phase 2 study. Lancet Oncol 2013; 14: 1121-8
11 Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T. et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): A randomised phase 3 trial. Lancet Oncol 2013; 14: 741-8
12 Kramar A, Bachelot T, Madrange T, Pierga JY, Kerbrat P, Espié M. et al Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial. Ann Oncol 2014; 25: 1563-70
13 Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P. et al. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: A multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol 2015; 26: 1333-40